浙江仙琚制药股份有限公司 2014 年第三季度报告正文 证券代码：002332 证券简称：仙琚制药 公告编号：2014-038 浙江仙琚制药股份有限公司 2014 年第三季度报告正文 1 浙江仙琚制药股份有限公司 2014 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人金敬德、主管会计工作负责人王瑶华及会计机构负责人(会计主管人员)赵素燕声明：保证 季度报告中财务报表的真实、准确、完整。 2 浙江仙琚制药股份有限公司 2014 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,865,042,946.45 | 2,753,781,655.8 ...

Financial Performance - The company's operating revenue for the first half of 2014 was CNY 1,190,483,041.23, representing a 4.88% increase compared to CNY 1,135,132,281.64 in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 44.70% to CNY 28,498,147.62 from CNY 51,530,688.53 year-on-year[21]. - Basic and diluted earnings per share both dropped by 40.00% to CNY 0.06 from CNY 0.10 in the same period last year[21]. - The net profit after deducting non-recurring gains and losses was CNY 28,130,424.28, down 45.03% from CNY 51,170,858.71 in the same period last year[21]. - The operating profit decreased by 56.03% to CNY 2,680.96 million, reflecting increased costs and expenses[32]. - The company expects a net profit attributable to shareholders for the period from January to September 2014 to range between 34.07 million and 45.43 million yuan, representing a decrease of 20.00% to 40.00% compared to the same period in 2013[66]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -77,011,994.03, slightly worse than CNY -75,363,104.90 in the previous year, a decline of 2.19%[21]. - The company's cash flow from operating activities was negative at CNY -77,011,994.03, indicating cash management challenges[33]. - Total cash inflow from operating activities was 1,315,823,565.50 CNY, while cash outflow was 1,392,835,559.53 CNY, resulting in a net cash outflow of 77,011,994.03 CNY[132]. - The total cash and cash equivalents at the end of the period were 217,510,741.40 CNY, down from 220,695,247.25 CNY in the previous period[133]. - The company reported a net increase in cash and cash equivalents of -60,812,277.75 CNY, compared to -66,937,137.56 CNY in the previous period, showing a slight improvement in cash management[133]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,804,479,514.07, an increase of 1.84% from CNY 2,753,781,655.82 at the end of the previous year[21]. - The total liabilities increased slightly to CNY 1,597,971,746.75 from CNY 1,571,760,413.78, indicating a growth of about 1.7%[120]. - Current assets totaled CNY 1,453,376,579.63, up from CNY 1,400,830,314.91 at the start of the period, reflecting a growth of approximately 3.7%[118]. - Accounts receivable increased significantly to CNY 450,788,663.82 from CNY 310,541,641.75, representing a growth of approximately 45%[118]. - Inventory decreased to CNY 436,329,471.14 from CNY 508,772,201.93, a reduction of about 14.2%[119]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[7]. - The total number of shares increased from 341,400,000 to 512,100,000, representing a 50% increase due to the capital reserve conversion[104]. - The largest shareholder, Xianju County State-owned Assets Investment Group Co., Ltd., held 21.55% of the shares, totaling 110,382,450 shares[107]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[109]. Research and Development - Research and development investment increased by 45.31% to CNY 31,851,511.17, reflecting a focus on product innovation[33]. - The company has established long-term collaborations with several research institutions, including the Chinese Academy of Sciences and Zhejiang University, to enhance its R&D capabilities[42]. - The company received clinical trial approval for new drugs, including the active pharmaceutical ingredient and tablet form of a new drug[36]. Corporate Governance and Compliance - The company has maintained compliance with corporate governance standards as per relevant laws and regulations[73]. - There were no significant litigation or arbitration matters reported during the period[74]. - The financial report for the half-year period has not been audited[98]. Financial Instruments and Accounting Policies - The financial statements comply with the enterprise accounting standards, ensuring a true and complete reflection of the company's financial status[151]. - The company uses Renminbi as its functional currency for accounting purposes[153]. - The company recognizes revenue from the sale of goods when the following conditions are met: transfer of significant risks and rewards of ownership to the buyer, no retention of management rights associated with ownership, reliable measurement of revenue amount, likelihood of economic benefits inflow, and reliable measurement of related costs[200].

Financial Performance - Revenue for the first quarter reached ¥559,063,295.52, an increase of 11.54% compared to ¥501,200,366.92 in the same period last year[8] - Net profit attributable to shareholders decreased by 54.96% to ¥8,058,198.09 from ¥17,891,108.22 year-on-year[8] - Basic and diluted earnings per share dropped by 60% to ¥0.02 from ¥0.05 in the same quarter last year[8] - The expected net profit for the first half of 2014 is projected to be between 20.61 million CNY and 30.92 million CNY, representing a decrease of 40% to 60% compared to the same period in 2013[25] - The net profit for the first half of 2013 was 51.53 million CNY, indicating a significant decline in profitability[25] Cash Flow - The net cash flow from operating activities was negative at -¥75,124,403.75, a decline of 6.05% compared to -¥70,840,400.62 in the previous year[8] - Net cash flow from financing activities decreased by 80.25% year-on-year, down by 211.16 million CNY, primarily due to increased cash payments for debt repayment[19] - The impact of exchange rate changes on cash and cash equivalents increased by 88.79% year-on-year, up by 191,100 CNY, mainly due to exchange rate fluctuations[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,731,252,719.58, a decrease of 0.82% from ¥2,753,781,655.82 at the end of the previous year[8] - Accounts receivable increased by 64.11%, rising by ¥199,097,500 to reflect higher sales and industry-specific collection cycles[17] - Short-term borrowings increased by 46.08%, amounting to an additional ¥300,790,500 due to increased borrowing activities[17] Shareholder Information - The number of shareholders at the end of the reporting period was 20,435[11] - The largest shareholder, Xianju County State-owned Assets Investment Group, holds 21.55% of the shares, totaling 73,588,300 shares[12] Expenses and Costs - Management expenses increased by 38.38% year-on-year, rising by 17.23 million CNY, mainly due to increased management costs[19] - Net profit attributable to shareholders decreased by 54.96% year-on-year, down by 9.83 million CNY, primarily due to increased fixed asset depreciation and comprehensive management costs[19] - Income tax expenses decreased by 36.07% year-on-year, down by 2.17 million CNY, mainly due to a decline in total profit[19] Performance Decline Reasons - The main reasons for the performance decline include increased fixed asset depreciation and rising comprehensive management costs[25]

Financial Performance - The company's operating revenue for 2013 was CNY 2,315,040,565.81, representing a 16.21% increase compared to CNY 1,992,191,544.54 in 2012[25] - The net profit attributable to shareholders decreased by 49.74% to CNY 60,591,468.84 from CNY 120,557,254.13 in the previous year[25] - The net profit after deducting non-recurring gains and losses was CNY 58,332,061.15, down 52.31% from CNY 122,313,136.72 in 2012[25] - Basic earnings per share decreased by 48.57% to CNY 0.18 from CNY 0.35 in the previous year[25] - The total profit for the period was CNY 70.09 million, down 54.47% compared to the previous year[35] - The company's operating costs increased by 26.26% to CNY 1,517.51 million[35] - The company's total revenue for 2013 was CNY 2,232,886,713.89, representing a year-on-year increase of 14.17% compared to CNY 1,955,760,020.54 in 2012[42] - The gross profit margin for the pharmaceutical sector was 34.25%, reflecting a decrease of 5.12% compared to the previous year[60] Cash Flow and Investments - The net cash flow from operating activities increased by 89.85% to CNY 63,461,725.59, compared to CNY 33,427,871.62 in 2012[25] - The company's operating cash inflow totaled CNY 2,601,401,761.77, representing a 23.33% increase compared to the previous year[58] - The total cash outflow from investment activities decreased by 47.21% to CNY 194,245,326.76, mainly due to reduced cash payments for fixed assets and other long-term assets[58] - The company reported a significant decrease in external investment, with an investment amount of ¥6,893,884.90, down 93.2% from ¥101,431,594.55 in the same period last year[69] Research and Development - Research and development expenditure increased by 32.71% to CNY 79,665,736.89, accounting for 3.44% of total revenue[51] - The company established a new research institute to enhance its R&D capabilities[39] - The company has obtained a total of 19 authorized patents as of the reporting period, showcasing its strong R&D capabilities in steroid drug development[67] Market and Sales - The main revenue sources were corticosteroids (39.84% of total revenue) and gynecological and contraceptive drugs (28.19% of total revenue), with sales of corticosteroids increasing by 9.04% to CNY 889,529,575.91[42] - The company sold 223,288.67 units in 2013, a 14.17% increase from 195,576 units in 2012, while production volume rose by 19.98% to 125,796.07 tons[42] - The company has developed a comprehensive sales network covering major hospitals and over 60,000 pharmacies nationwide, which is crucial for future growth[66] Corporate Governance - The company emphasizes the importance of corporate governance and shareholder rights protection, ensuring timely and accurate information disclosure[108] - The company has maintained a governance structure that aligns with the requirements of the Company Law and the China Securities Regulatory Commission[187] - The independent directors actively participated in board meetings and shareholder meetings, fulfilling their responsibilities to protect shareholder interests[192] Environmental and Social Responsibility - The company is committed to environmental protection and sustainable development, implementing clean production and energy-saving measures[110] - The company has established wastewater treatment facilities with a design capacity of 4000 tons per day and air treatment facilities with a capacity of 90,000 cubic meters per hour[114] - The company actively participates in social responsibility initiatives, supporting local education, culture, and health[112] Future Outlook and Strategic Plans - The company provided a future outlook projecting a revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion[161] - New product development efforts include the introduction of three innovative drug formulations expected to enter the market in Q2 2014[161] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[161] Risks and Challenges - The company faces risks including policy price reductions and fluctuations in raw material prices, which may impact future performance[14] - The company anticipates potential mismatches between investment scale and returns, which may extend the payback period for investments due to market changes[98] - The company is exposed to raw material price volatility risks, particularly for key ingredients like saponins, which may affect product costs[97]